Multi-omics model to predict treatment response in early triple-negative breast cancer
Official title: Establishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study
Run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · NCT07773818 · Data updated 2026-11-12
A multimodal approach tests whether combining clinical data, imaging, pathology, and molecular data can predict which early TNBC patients will respond to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | Women only |
| Enrollment | 32 (estimated) |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | August 6, 2026 |
| Main results expected | September 1, 2028 |
| Study ends | September 1, 2029 |
| Registry record updated | August 19, 2026 |
| Trial ID | NCT07773818 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are participants from the UPGRADE-TNBC study population with available multimodal data (clinical, imaging, pathology, and molecular sequencing).
✕Probably not a fit
Patients not represented in the UPGRADE-TNBC cohort or lacking multimodal data may not benefit from the predictive model.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study uses an established high-quality TNBC sample repository from the UPGRADE-TNBC project and applies a meta-learning strategy to integrate diverse data sources. The goal is to build a predictive model for treatment response using a small-sample learning framework across clinical, radiomics, pathological, and molecular sequencing data. The study aims to identify patient subgroups that are more likely to benefit from specific drug combinations, guiding personalized therapy for early-stage TNBC.
Why it matters
Potential benefit: If successful, the model could help tailor treatments for individual patients and improve responses in early TNBC.
How similar studies have gone: Past studies using multimodal data and meta-learning approaches have shown promise in predicting treatment responses, but this exact approach in early TNBC is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The UPGRADE-TNBC Study Population Exclusion Criteria: * Populations outside the UPGRADE-TNBC study
Where it's running
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Xue Wang
- Email: wxyxyuki@163.com
- Phone: 86-010-87787242
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cadonilimab and Lenvatinib in advanced kidney cancer
This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.
-
Neoadjuvant therapy with nimotuzumab, toripalimab, nab-paclitaxel, and cisplatin for locally advanced head and neck cancer
This study tests a pre-surgery treatment combining targeted therapy, immunotherapy, and chemotherapy to see if it helps patients with locally advanced, resectable head and neck squamous cell carcinoma.
-
Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer
This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.
-
Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread
This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.
-
Three-dimensional lattice radiotherapy with PD-1/PD-L1 inhibitors for advanced solid tumors
This study tests whether adding lattice radiotherapy to PD-1/PD-L1 inhibitors is safe and helps people with advanced solid tumors that have grown or spread.
-
Radiotherapy target-volume choices in locally advanced esophageal cancer during immunotherapy
This observational study looks at how doctors outline the radiation area for locally advanced esophageal squamous cell cancer patients treated with radiotherapy and immunotherapy to see which approaches correlate with better outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.